Cover Image
市場調查報告書

美國的抗凝血劑市場:2016∼2020年

Anticoagulants Market in the US 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 358379
出版日期 內容資訊 英文 89 Pages
訂單完成後即時交付
價格
Back to Top
美國的抗凝血劑市場:2016∼2020年 Anticoagulants Market in the US 2016-2020
出版日期: 2016年05月16日 內容資訊: 英文 89 Pages
簡介

抗凝血劑,用於治療血栓造成的疾病經過80年以上。作為深部靜脈血栓症、肺栓塞、心房纖維顫動、急性冠狀動脈症候群等首先的救命手段,不過,隨時代變遷正逐漸變成比到目前為止的治療方法安全有效的新口服抗凝血劑。美國的抗凝血劑市場,預計2016∼2020年以年複合成長率6.67%擴大。

本報告提供美國的抗凝血劑市場相關調查,市場現狀及成長預測,市場課題,各地區趨勢,以及主要供應商簡介彙整。

第1章 摘要整理

第2章 本報告的範圍

第3章 調查方法

第4章 簡介

第5章 抗凝血劑:概要

  • 血液的凝固
  • 抗凝血劑的作用機制

第6章 償付方案

第7章 抗凝血劑拮抗劑

第8章 美國核准的抗凝血劑

第9章 抗凝血劑產品研發線

第10章 市場情況

  • 全球抗凝血劑市場
  • 美國的抗凝血劑市場
  • 波特的五力分析

第11章 各給藥途徑市場區隔

  • 口服
  • 注射

第12章 各類藥物市場區隔

第13章 各用途市場市場區隔

第14章 推動市場的要素

第15章 促進要素的影響

第16章 市場課題

第17章 促進要素與課題的影響

第18章 市場趨勢

第19章 供應商環境

  • 競爭模式
  • 2015年的市場分析
  • 美國的主要供應商
  • Johnson & Johnson
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Sanofi
  • 美國的今後活躍的供應商
  • 第一三共株式會社
  • 其他值得注意的供應商

第20章 附錄

第21章 關於Technavio

圖表

目錄
Product Code: IRTNTR9372

About the Anti-Coagulant Drugs Market

Anticoagulants have been used for over 80 years to treat clotting disorders. It is used as a first line of defense for disorders such as deep vein thrombosis (DVT), pulmonary embolism, AF, and acute coronary syndrome. With the advent of time, traditional therapies are replaced by novel oral anticoagulants, which have better safety and efficacy profiles.

The 1990s saw rapid development in the field of direct thrombin inhibitors. Though these drugs, such as hirudin, have been in use from the early 19th century, they were accepted with the development of genetic engineering technology. The recombinant forms, such as desirudin, are also available in the market. During the same period, the focus shifted toward the development of factor Xa inhibitors, and by early 2000s, the first indirect factor Xa inhibitor, fondaparinux, was released into the market. These drugs were administered by parenteral route.

Technavio's analysts forecast the anti-coagulants market in the US to grow at a CAGR of 6.67% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the anti-coagulants market in the US for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generics drugs used to treat coagulation disorders. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market.

Technavio's report, Anti-Coagulants Market in the US 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Johnson & Johnson
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Sanofi
  • Daiichi Sankyo

Other Prominent Vendors

  • Armatheon Inc.
  • Aspen
  • AstraZeneca
  • Bayer
  • Cellceutix
  • Cosmo Pharmaceuticals SA
  • CSL Behring, Eisai, GSK
  • Marathon Pharmaceuticals LLC
  • Ockham Biotech
  • Perosphere
  • Portola Pharmaceuticals
  • Sagent Pharmaceuticals Inc.
  • The Medicines Company
  • Urigen Pharmaceuticals Inc.
  • Valeant Pharmaceuticals

Market driver

  • Growing prevalence of coagulation disorders
  • For a full, detailed list, view our report

Market challenge

  • Side-effects associated with drugs
  • For a full, detailed list, view our report

Market trend

  • Expected exploitation of new therapeutic use
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Anticoagulants: An overview

  • Coagulation of blood
  • Mechanism of action (MOA) of anticoagulants

PART 06: Reimbursement scenario

  • US healthcare reform
  • Reimbursement for prothrombin time/international normalized ratio (PT/INR) tests

PART 07: Anticoagulant reversal agents

PART 08: Approved anticoagulants in US

PART 09: Anticoagulants pipeline portfolio

  • Rivaroxaban
  • Tecarfarin
  • Betrixaban (LY517717)
  • ISIS-FXI antisense
  • LMW Heparin MMX
  • URG101
  • Heparin
  • FXI antibody
  • FXI inhibitor
  • Heparin plus DNAse
  • Heparin plus other inhaled drug

PART 10: Market landscape

  • Global anticoagulants market
  • Anticoagulants market in US
  • Five forces analysis

PART 11: Market segmentation by ROA

  • Oral anticoagulants
  • Injectable anticoagulants

PART 12: Market segmentation by drug class

  • Factor Xa inhibitors
  • Direct thrombin inhibitors
  • Heparin
  • Vitamin K antagonists

PART 13: Market segmentation by application

  • DVT
  • PE
  • Acute coronary syndrome
  • AF
  • Hemodialysis
  • Coronary angioplasty
  • Surgeries

PART 14: Market drivers

  • Growing prevalence of coagulation disorders
  • Increase in number of surgical procedures
  • Increased acceptance of NOACs

PART 15: Impact of drivers

PART 16: Market challenges

  • Extensive use of generic products
  • Side-effects associated with drugs
  • High cost of NOACs
  • Unmet needs for anticoagulant reversal agents

PART 17: Impact of drivers and challenges

PART 18: Market trends

  • Expected exploitation of new therapeutic use
  • Patient assistance programs
  • Declining shares of heparin market

PART 19: Vendor landscape

  • Competitive scenario
  • Market analysis 2015
  • Key vendors of anticoagulants market in US
  • Johnson & Johnson
  • Bristol-Myers Squibb
  • Boehringer Ingelheim
  • Sanofi
  • Upcoming vendors in anticoagulants market in US
  • Daiichi Sankyo
  • Other prominent vendors

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Timeline for development of anticoagulants
  • Exhibit 03: Process of blood coagulation
  • Exhibit 04: Mechanism of blood coagulation
  • Exhibit 05: Comparison of US healthcare system before and after reforms
  • Exhibit 06: Major anticoagulant reversal agents commonly used in market
  • Exhibit 07: Reversal agents approved by FDA for new oral anticoagulants
  • Exhibit 08: Pipeline portfolio: Anticoagulant reversal agents
  • Exhibit 09: Approved anticoagulants in US
  • Exhibit 10: Pipeline portfolio: Anticoagulant drugs
  • Exhibit 11: Global anticoagulants market 2015-2020 ($ billions)
  • Exhibit 12: Percentage share of US anticoagulants market in global market
  • Exhibit 13: Anticoagulants market in US 2015-2020 ($ billions)
  • Exhibit 14: Five forces analysis
  • Exhibit 15: Segmentation of anticoagulants market in US based on ROA
  • Exhibit 16: Market segmentation of anticoagulants market in US based on ROA 2015
  • Exhibit 17: Comparison of US anticoagulants market with global anticoagulants market 2015
  • Exhibit 18: Percentage of population treated by NOACs based on disease type in US 2015
  • Exhibit 19: Factors determining use of NOACs (based on their importance)
  • Exhibit 20: Percentage of individuals with AF treated by anticoagulants in US 2015
  • Exhibit 21: Percentage of individuals with DVT/PE treated by anticoagulants in US 2015
  • Exhibit 22: Classes of oral anticoagulants based on revenue 2015
  • Exhibit 23: Oral anticoagulants market in US 2015-2020 ($ billions)
  • Exhibit 24: Classes of injectable anticoagulants based on revenue 2015
  • Exhibit 25: Injectable anticoagulants market in the US 2015-2020 ($ billions)
  • Exhibit 26: Anticoagulants market in US by ROA 2015-2020
  • Exhibit 27: Anticoagulants market in US: YoY growth and revenue based on ROA 2015-2020
  • Exhibit 28: Segmentation of anticoagulants market in US based on drug class
  • Exhibit 29: Segmentation of anticoagulants market in US based on drug class 2015
  • Exhibit 30: Anticoagulants market in US in global anticoagulant drugs market 2015
  • Exhibit 31: Segmentation of factor Xa inhibitors in US 2015
  • Exhibit 32: Approval of factor Xa inhibitor drugs in US
  • Exhibit 33: Factor Xa inhibitor drugs market in US 2015-2020 ($ billions)
  • Exhibit 34: Some direct thrombin inhibitor drugs approved in US
  • Exhibit 35: Direct thrombin inhibitors market segmentation by ROA 2015
  • Exhibit 36: Direct thrombin inhibitor drugs market in US 2015-2020 ($ billions)
  • Exhibit 37: Segmentation of global heparin market by product type 2015
  • Exhibit 38: Global heparin market 2015-2020 ($ billions)
  • Exhibit 39: Heparin market in US 2015-2020 ($ billions)
  • Exhibit 40: Vitamin K antagonists market in US 2015-2020 ($ millions)
  • Exhibit 41: Anticoagulants market in US by drug class 2015-2020
  • Exhibit 42: Anticoagulants market in US: YoY growth and revenue based on drug class 2015-2020
  • Exhibit 43: Expected growth of older population in US 2010-2050
  • Exhibit 44: Impact of drivers
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Share of the major anticoagulant drugs in US 2013-2015 ($ billions)
  • Exhibit 47: Johnson & Johnson: YoY revenue and growth rate of Xarelto in US 2013-2015 ($ millions)
  • Exhibit 48: Johnson & Johnson: Key takeaways
  • Exhibit 49: BMS: YoY revenue and growth rate of Eliquis in US 2013-2015 ($ millions)
  • Exhibit 50: BMS: Key takeaways
  • Exhibit 51: Boehringer Ingelheim: YoY revenue and growth rate of Pradaxa (global) 2013-2015 ($ billions)
  • Exhibit 52: Boehringer Ingelheim: Key takeaways
  • Exhibit 53: Sanofi: YoY revenue and growth rate of Lovenox in US 2013-2015 ($ millions)
  • Exhibit 54: Geographical segmentation of Lovenox 2015
  • Exhibit 55: Sanofi: Key takeaways
  • Exhibit 56: Key takeaways
Back to Top